Report Overview

Increasing incidence of cancer in India, government support and initiatives, together with increased financing for cancer research and treatment, and collaborations & partnerships between pharmaceutical companies, research institutions, and healthcare providers are expected to drive the growth of the India Cancer Immunotherapy market during the forecast period between 2024 and 2030.

India Cancer Immunotherapy Market – Industry Trends & Forecast Report, 2030

The India Cancer Immunotherapy Market size was estimated at USD 98.37 billion in 2023. During the forecast period between 2024 and 2030, the India Cancer Immunotherapy Market size is projected to grow at a CAGR of 6.39% reaching a value of USD 102.11 billion by 2030. The increased incidence of cancer in India is a major cause, needing sophisticated treatment options such as immunotherapy. The Global Cancer Observatory (GLOBOCAN) predicts 19.3 million incident cancer cases worldwide in 2020. India ranks third after China and the United States of America. GLOBOCAN anticipated that cancer cases in India would climb to 2.08 million by 2040, representing a 57.5 percent increase from 2020. Government support and initiatives, together with increased financing for cancer research and treatment, help to expand the immunotherapy business in India. Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers are critical to the advancement and expansion of immunotherapy solutions in the Indian market.

Cancer Immunotherapy – Overview

Immunotherapy is a type of cancer treatment that stimulates the immune system to fight cancer. The immune system helps the body fight infections and other disorders. Immunotherapy is a type of biological therapy. Biological therapy is a treatment that employs compounds derived from live creatures to combat cancer. As part of its regular function, the immune system discovers and destroys aberrant cells, which most likely prevents or slows the progression of many malignancies. For example, immune cells can be detected in and surrounding tumours. These cells, known as tumor-infiltrating lymphocytes, or TILs, indicate that the immune system is responding to the tumour. People with TIL-containing tumours frequently perform better than those without.

India Cancer Immunotherapy Market

Growth Drivers

Increasing Cancer Incidence

The rising prevalence of cancer in India is a primary driver, necessitating advanced treatment options like immunotherapy. According to the National Cancer Registry Programme Report 2020, “the expected number of cancer incidents in India for 2022 is 14,61,427 (crude rate: 100.4 per 100,000). In India, one out of every nine people is likely to develop cancer over his or her lifetime. Lymphoid leukaemia (boys: 29.2% and girls: 24.2%) was the most common malignancy in children aged 0 to 14. The number of cancer cases is expected to increase by 12.8% in 2025 compared to 2020”. Thus, as the country's cancer prevalence rises, the market for cancer immunotherapy is rapidly developing. The high incidence of cancer in India has created a significant market opportunity for immunotherapy treatments, reflecting the urgent need for effective remedies.

Challenges

Infrastructure and Expertise

Inadequate infrastructure and a scarcity of competent immunotherapy specialists provide challenges. Establishing and sustaining immunotherapy infrastructure, as well as training healthcare personnel in this discipline, are critical to its wider acceptance. The India Cancer Immunotherapy Market's potential growth is restricted by the requirement for significant expenditures in infrastructure development and medical knowledge. This difficulty is especially important in clinical trials for cancer immunotherapies, which require a strong infrastructure and specialized expertise. Oncology Specialist Nurses (OSNs) are trained to care for patients receiving cancer treatments such as chemotherapy, surgery, radiation therapy, and palliative care. These specialized nurses are proficient in delivering cancer prevention and early detection-related information to the patient’s caretakers. Dr Sanjiv Chopra, CEO of Tata Trusts Cancer Care Programme, told ETHealthworld's that the World Health Organisation (WHO) reports a global nursing shortage. In India, there is a deficit of more than 20 lakh nurses. In India, the nurse-to-population ratio is 1.7:1000, as opposed to the needed 3:1000. To overcome this impediment, healthcare stakeholders must work together, including government initiatives, business sector investments, and cooperation with international organisations, to bridge India's cancer immunotherapy infrastructure and expertise gaps.

Impact of Escalating Geopolitical Tensions on India Cancer Immunotherapy Market

Escalating geopolitical tensions may have a varied impact on the India cancer immunotherapy market. Geopolitical conflicts can disrupt global supply chains, limiting the availability of critical components for immunotherapy medications and equipment in India. This can cause therapeutic delays and may have an influence on patient outcomes. Geopolitical uncertainty may erode investor confidence, reducing healthcare investment, especially cancer immunotherapy research and development. International collaborations in cancer immunotherapy research may be jeopardised, limiting the flow of knowledge and progress in the field. Geopolitical tensions may result in changes in regulatory frameworks, influencing the clearance processes for new immunotherapies in India. Stakeholders in India's cancer immunotherapy business must actively follow geopolitical changes, react to potential hurdles, and cultivate resilience.

India Cancer Immunotherapy Market

Segmental Coverage

India Cancer Immunotherapy Market – By Type

Based on type, the India cancer immunotherapy market is segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators. The monoclonal antibody segment dominates India's cancer immunotherapy market. This is owing to the unique features of monoclonal antibodies, which allow them to influence the immune system, resulting in their widespread use in cancer immunotherapy. Significant investments in research and development have been made in monoclonal antibody-based therapeutics, resulting in the creation of novel and successful treatments for many cancers.  Monoclonal antibodies offer fewer adverse effects than other immunotherapeutic methods, resulting in higher patient acceptance and compliance.                                                                  

India Cancer Immunotherapy Market – By Application

Based on applications, the India cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. During the forecast period, the lung cancer is anticipated to hold a significant market share. Lung cancer is one of the most common malignancies in India, accounting for a major portion of the total cancer burden. The increasing frequency of lung cancer raises the need for effective immunotherapy treatments that target this particular type of disease. In India, lung cancer is responsible for 5.9% of all cancers and 8.1% of all cancer-related fatalities. Nearly 80% of lung cancer patients smoke. Increased awareness of lung cancer symptoms, combined with developments in testing procedures, leads to earlier detection. As a result, there is an increasing demand for targeted immunotherapies that address the unique problems associated with lung cancer treatment.                                                                                                                                                 

India Cancer Immunotherapy Market – By Region

The in-depth research report on the India Cancer Immunotherapy market covers several major countries across the region: North India, South India, East India, and West India. The dominance of a specific region in the market can be influenced by various factors such as the concentration of leading healthcare facilities, and research institutions, and the prevalence of cancer in that region. Some of the top 10 hospitals in India are in states of Delhi, Mumbai, Chennai, Bangalore, Hyderabad, and Kolkata and so true with the research institutions for cancer such as Tata Memorial Centre - Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) which is located in Mumbai, Maharashtra, ACTREC is a top-ranking tertiary cancer research center, and All India Institute of Medical Sciences (AIIMS) Delhi. According to NIH, the North-Eastern (NE) region has the highest incidence of cancer in India and is also burdened by a higher prevalence of risk factors and inadequate cancer treatment facilities.

Competitive Landscape

Major players operating in the India Cancer Immunotherapy Market include Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Lilly, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Gilead Sciences, Inc, GSK plc, Johnson & Johnson, Sanofi. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

• In October 2023 - MSD has received approval from the Drug Controller General of India (DCGI) for Keytruda (pembrolizumab) in the treatment of triple-negative breast cancer and renal cell carcinoma in adults. Keytruda is approved to treat high-risk early-stage and metastatic triple-negative breast cancer in patients at high risk of recurrence. With its approval, Keytruda became the first immunotherapy approved for the adjuvant treatment of select patients with renal cell carcinoma and early-stage triple-negative breast cancer. 

• In January 2024 - Glenmark announced a collaboration with its clinical-stage biotech business Ichnos Sciences to speed novel drug discovery in cancer treatment.

Scope of the Report

Attributes	Details
Years Considered	Historical Data – 2019–2030
	Base Year – 2023
	Estimated Year – 2024
	Forecast Period – 2024–2030
Facts Covered	Revenue in USD billion
Market Coverage	North India, South India, East India, West India
Product / Product Segmentation	Type, Application, End User, Region
Key Players	Astellas Pharma Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb, Lilly, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Gilead Sciences, Inc, GSK plc, Johnson & Johnson, Sanofi

 

By Type

• Monoclonal Antibodies

• Cancer Vaccines

• Checkpoint Inhibitors

• Immunomodulators

By Application

• Lung Cancer

• Breast Cancer

• Colorectal Cancer

• Melanoma

• Prostate Cancer

• Head and Neck Cancer

• Others

By End User

• Hospitals

• Cancer Research Centers

• Clinics

By Region

• North India

• South India

• East India

• West India

1. Research Framework
   1. Research Objective
   2. Product Overview
   3. Market Segmentation
2. Executive Summary
3. India Cancer Immunotherapy Market Insights
   1. Industry Value Chain Analysis
   2. DROC Analysis
      1. Growth Drivers
         1. Increasing cancer incidence
         2. Government initiatives and funding
         3. Collaborations and partnerships
      2. Restraints
         1. High treatment costs
         2. Stringent regulatory requirements and approval processes
         3. Side effects and safety concerns
      3. Opportunities
         1. Advancements in research and development
         2. Patient awareness and education
      4. Challenges
         1. Infrastructure and expertise
         2. Resistance mechanisms
   3. Technology Advancements/Recent Developments
   4. Regulatory Framework
   5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
4. India Cancer Immunotherapy Market: Marketing Strategies
5. India Cancer Immunotherapy Market Overview
   1. Market Size & Forecast, 2019-2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Type
         1. Monoclonal Antibodies
         2. Cancer Vaccines
         3. Checkpoint Inhibitors
         4. Immunomodulators
      2. By Application
         1. Lung Cancer
         2. Breast Cancer
         3. Colorectal Cancer
         4. Melanoma
         5. Prostate Cancer
         6. Head and Neck Cancer
         7. Others
      3. By End User
         1. Hospitals
         2. Cancer Research Centers
         3. Clinics
      4. By Region
         1. North India
         2. South India
         3. East India
         4. West India
6. North India Cancer Immunotherapy Market
   1. Market Size & Forecast, 2019-2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Type
      2. By Application
      3. By End User
7. South India Cancer Immunotherapy Market
   1. Market Size & Forecast, 2019-2030
   2. By Value (USD Billion)
   3. Market Share & Forecast
      1. By Type
      2. By Application
      3. By End User
8. East India Cancer Immunotherapy Market
   1. Market Size & Forecast, 2019-2030
   2. By Value (USD Billion)
   3. Market Share & Forecast
      1. By Type
      2. By Application
      3. By End User
9. West India Cancer Immunotherapy Market
   1. Market Size & Forecast, 2019-2030
      1. By Value (USD Billion)
   2. Market Share & Forecast
      1. By Type
      2. By Application
      3. By End User
10. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. India Cancer Immunotherapy Company Market Share Analysis, 2023
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Geopolitical Tension in India Cancer Immunotherapy Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
    1. Astellas Pharma Inc.
    2. AstraZeneca
    3. Bayer AG
    4. Bristol-Myers Squibb
    5. Lilly
    6. F. Hoffmann-La Roche Ltd
    7. Merck & Co., Inc.
    8. Novartis AG
    9. Pfizer Inc.
    10. Gilead Sciences, Inc
    11. GSK plc
    12. Johnson & Johnson
    13. Sanofi
    14. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
    1.       Qualitative Research
       1.   Primary & Secondary Research
    2.       Quantitative Research
    3.       Market Breakdown & Data Triangulation
       1.   Secondary Research
       2.   Primary Research
    4.       Breakdown of Primary Research Respondents, By Region
    5.       Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

 

 

 

 

 

List of Figures

 

Figure 1       India Cancer Immunotherapy Segmentation

Figure 2       India Cancer Immunotherapy Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2023

Figure 4       India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Figure 5       India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Figure 6       India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Figure 7       India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Figure 8       India Cancer Immunotherapy Market Share, By Region, By Value, 2019-2030

Figure 9       North India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Figure 10     North India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Figure 11     North India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Figure 12     North India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Figure 13     South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Figure 14     South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Figure 15     South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Figure 16     South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Figure 17     East India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Figure 18     East India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Figure 19     East India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Figure 20     East India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Figure 21     South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Figure 22     South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Figure 23     South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Figure 24     South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Figure 25     West India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Figure 26     West India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Figure 27     West India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Figure 28     West India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

 

List of Tables

 

Table 1        India Cancer Immunotherapy Segmentation

Table 2        India Cancer Immunotherapy Market Value Chain Analysis

Table 3        Company Market Size Analysis, 2023

Table 4        India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Table 5        India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Table 6        India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Table 7        India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Table 8        India Cancer Immunotherapy Market Share, By Region, By Value, 2019-2030

Table 9        North India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Table 10      North India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Table 11      North India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Table 12      North India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Table 13      South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Table 14      South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Table 15      South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Table 16      South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Table 17      East India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Table 18      East India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Table 19      East India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Table 20      East India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Table 21      South India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Table 22      South India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Table 23      South India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Table 24      South India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Table 25      West India Cancer Immunotherapy Market Size, By Value (USD Billion), 2019-2030

Table 26      West India Cancer Immunotherapy Market Share, By Type, By Value, 2019-2030

Table 27      West India Cancer Immunotherapy Market Share, By Application, By Value, 2019-2030

Table 28      West India Cancer Immunotherapy Market Share, By End User, By Value, 2019-2030

Table 29      Astellas Pharma Inc. Company Overview

Table 30      Astellas Pharma Inc. Financial Overview

Table 31      AstraZeneca Company Overview

Table 32      AstraZeneca Financial Overview

Table 33      Bayer AG Company Overview

Table 34      Bayer AG Financial Overview

Table 35      Bristol-Myers Squibb Company Overview

Table 36      Bristol-Myers Squibb Financial Overview

Table 37      Lilly Company Overview

Table 38      Lilly Financial Overview

Table 39      F. Hoffmann-La Roche Ltd Company Overview

Table 40      F. Hoffmann-La Roche Ltd Financial Overview

Table 41      Merck & Co., Inc. Company Overview

Table 42      Merck & Co., Inc. Financial Overview

Table 43      Novartis AG Company Overview

Table 44      Novartis AG Financial Overview

Table 45      Pfizer Inc. Company Overview

Table 46      Pfizer Inc. Financial Overview

Table 47      Gilead Sciences, Inc Company Overview

Table 48      Gilead Sciences, Inc Financial Overview

Table 49      GSK plc Company Overview

Table 50      GSK plc Financial Overview

Table 51      Johnson & Johnson Company Overview

Table 52      Johnson & Johnson Financial Overview

Table 53      Sanofi Company Overview

Table 54      Sanofi Financial Overview